Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAG regimen in newly diagnosed AML
NCT06536010Phase 2Recruiting
- Start
- Nov 2021
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML). Primary endpoint: Complete Remission at 2 months. Started Nov 2021; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06536010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536010.